Hybridoma, hCD40L-M91 [M91, hCD40L-M91]
Hybridoma, hCD40L-M91 [M91, hCD40L-M91]
规格:
货期:
编号:TS212047
品牌:Testobio
| 产品名称： | Hybridoma, hCD40L-M91 M91, hCD40L-M91 |
|---|---|
| 商品货号： | TS212047 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma:lymphoblast B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain: BALB/cxa0 (B cell); BALB/c (myeloma) |
| Applications： | Spleen cells were fused with either Ag8.653 or NS1 mouse myeloma cells (the specific line used was not specified). |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with either Ag8.653 or NS1 mouse myeloma cells (the specific line used was not specified). |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human CD40 ligand (CD154, CD40L) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human CD40 ligand (CD154, CD40L) |
| Comments： | Animals were immunized with human CD40 ligand (CD154, CD40L). Spleen cells were fused with either Ag8.653 or NS1 mouse myeloma cells (the specific line used was not specified). The antibody recognizes the human CD40L polypeptide. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml. Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype： | mouse IgG1 , IgG1 |
| Name of Depositor： | Immunex Corporation |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Armitage RJ, et al. Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same. US Patent 5,961,974 dated Oct 5 1999 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
Hybridoma, hCD40L-M91 [M91, hCD40L-M91]
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Hybridoma, hCD40L-M91 M91, hCD40L-M91 |
|---|---|
| 商品货号： | TS212047 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma:lymphoblast B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain: BALB/cxa0 (B cell); BALB/c (myeloma) |
| Applications： | Spleen cells were fused with either Ag8.653 or NS1 mouse myeloma cells (the specific line used was not specified). |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with either Ag8.653 or NS1 mouse myeloma cells (the specific line used was not specified). |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human CD40 ligand (CD154, CD40L) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human CD40 ligand (CD154, CD40L) |
| Comments： | Animals were immunized with human CD40 ligand (CD154, CD40L). Spleen cells were fused with either Ag8.653 or NS1 mouse myeloma cells (the specific line used was not specified). The antibody recognizes the human CD40L polypeptide. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml. Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype： | mouse IgG1 , IgG1 |
| Name of Depositor： | Immunex Corporation |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Armitage RJ, et al. Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same. US Patent 5,961,974 dated Oct 5 1999 |
